{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:09:25Z","timestamp":1793966965623,"version":"4.8.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We retrospectively screened 350,116 electronic health records (EHRs) to identify suspected patients for Pompe disease. Using these suspected patients, we then describe their phenotypical characteristics and estimate the prevalence in the respective population covered by the EHRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We applied Symptoma's Artificial Intelligence-based approach for identifying rare disease patients to retrospective anonymized EHRs provided by the \u201cUniversity Hospital Salzburg\u201d clinic group. Within 1 month, the AI screened 350,116 EHRs reaching back 15 years from five hospitals, and 104 patients were flagged as probable for Pompe disease. Flagged patients were manually reviewed and assessed by generalist and specialist physicians for their likelihood for Pompe disease, from which the performance of the algorithms was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 104 patients flagged by the algorithms, generalist physicians found five \u201cdiagnosed,\u201d 10 \u201csuspected,\u201d and seven patients with \u201creduced suspicion.\u201d After feedback from Pompe disease specialist physicians, 19 patients remained clinically plausible for Pompe disease, resulting in a specificity of 18.27% for the AI. Estimating from the remaining plausible patients, the prevalence of Pompe disease for the greater Salzburg region [incl. Bavaria (Germany), Styria (Austria), and Upper Austria (Austria)] was one in every 18,427 people. Phenotypes for patient cohorts with an approximated onset of symptoms above or below 1 year of age were established, which correspond to infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study shows the feasibility of Symptoma's AI-based approach for identifying rare disease patients using retrospective EHRs. Via the algorithm's screening of an entire EHR population, a physician had only to manually review 5.47 patients on average to find one suspected candidate. This efficiency is crucial as Pompe disease, while rare, is a progressively debilitating but treatable neuromuscular disease. As such, we demonstrated both the efficiency of the approach and the potential of a scalable solution to the systematic identification of rare disease patients. Thus, similar implementation of this methodology should be encouraged to improve care for all rare disease patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2023.1108222","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:59:53Z","timestamp":1682038793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["An artificial intelligence-based approach for identifying rare disease patients using retrospective electronic health records applied for Pompe disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Simon","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jama","family":"Nateqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Weingartner-Ortner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Gruarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Marling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinzenz","family":"Pilgram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian B.","family":"Lagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13023-020-01587-2","article-title":"Why is misdiagnosis more likely among some people with rare diseases than others? Insights from a population-based cross-sectional study in China","volume":"15","author":"Dong","year":"2020","journal-title":"Orphanet J Rare Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"ii21","DOI":"10.1136\/bmjqs-2012-001615","article-title":"The incidence of diagnostic error in medicine","volume":"22","author":"Graber","year":"2013","journal-title":"BMJ Qual Saf."},{"key":"B3","year":""},{"key":"B4","unstructured":"Regulation (EC) No 141\/2000 of the European Parliament o... - EUR-Lex"},{"key":"B5","unstructured":"FAQs About Rare Diseases | Genetic and Rare Diseases Information Center (GARD) - an NCATS Program"},{"key":"B6","volume-title":"The Voice of 12,000 Patients","author":"Kole","year":"2009"},{"key":"B7","unstructured":"EURORDIS - The Voice of Rare Disease Patients in Europe - International Joint Recommendations to Address Specific Needs of Undiagnosed Rare Disease Patients"},{"key":"B8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/jmd2.12062","article-title":"Extent, impact, and predictors of diagnostic delay in Pompe disease: a combined survey approach to unveil the diagnostic odyssey","volume":"49","author":"Lagler","year":"2019","journal-title":"JIMD Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.rppnen.2017.02.004","article-title":"Prevalence of late-onset Pompe disease in Portuguese patients with diaphragmatic paralysis - DIPPER study","volume":"23","author":"Guimar\u00e3es","year":"2017","journal-title":"Rev Port Pneumol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.nmd.2015.04.008","article-title":"Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: a Spanish cohort","volume":"25","author":"Guti\u00e9rrez-Rivas","year":"2015","journal-title":"Neuromuscul Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1212\/WNL.0000000000002758","article-title":"Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness","volume":"87","author":"Lukacs","year":"2016","journal-title":"Neurology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jnnp-2014-310164","article-title":"LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population","volume":"87","author":"Musumeci","year":"2016","journal-title":"J Neurol Neurosurg Psychiatr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.19082\/4886","article-title":"Evaluation prevalence of Pompe disease in Iranian patients with myopathies of unknown etiology","volume":"9","author":"Tehrani","year":"2017","journal-title":"Electron Physician."},{"key":"B14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"100734","DOI":"10.1016\/j.ymgmr.2021.100734","article-title":"Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database","volume":"27","author":"Park","year":"2021","journal-title":"Mol Genet Metab Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00415-017-8686-6","article-title":"Pompe disease in Austria: clinical, genetic and epidemiological aspects","volume":"265","author":"L\u00f6scher","year":"2018","journal-title":"J Neurol."},{"key":"B17","first-page":"141","article-title":"Minutes of the European pompe consortium (EPOC) meeting march 27 to 28, 2015, Munich, Germany","volume":"34","author":"Schoser","year":"2015","journal-title":"Acta Myol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s10038-021-00935-9","article-title":"Phenotypic implications of pathogenic variant types in Pompe disease","volume":"66","author":"Viamonte","year":"2021","journal-title":"J Hum Genet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajmg.c.31318","article-title":"The genotype-phenotype correlation in Pompe disease","author":"Kroos","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41436-020-01038-0","article-title":"Health and economic outcomes of newborn screening for infantile-onset Pompe disease","volume":"23","author":"Richardson","year":"2021","journal-title":"Genet Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijns6010009","article-title":"The first year experience of newborn screening for Pompe disease in California","volume":"6","author":"Tang","year":"2020","journal-title":"Int J Neonatal Screen."},{"key":"B22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ymgme.2012.04.013","article-title":"Algorithm for Pompe disease newborn screening: results from the Taiwan screening program","volume":"106","author":"Chiang","year":"2012","journal-title":"Mol Genet Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s13023-021-02146-z","article-title":"Current status of newborn screening for Pompe disease in Japan","volume":"16","author":"Sawada","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/bmj.311.7020.1621","article-title":"Clinical trials and rare diseases: a way out of a conundrum","volume":"311","author":"Lilford","year":"1995","journal-title":"BMJ."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.bbadis.2015.02.008","article-title":"Rare disease policies to improve care for patients in Europe","volume":"1852","author":"Rodwell","year":"2015","journal-title":"Biochim Biophys Acta."},{"key":"B26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-020-01374-z","article-title":"Diagnosis support systems for rare diseases: a scoping review","volume":"15","author":"Faviez","year":"2020","journal-title":"Orphanet J Rare Dis."},{"key":"B27","unstructured":"Barriers to Medical Innovation2002"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e14197","DOI":"10.2196\/14197","article-title":"Barriers and facilitators to the implementation of eHealth services: systematic literature analysis","volume":"21","author":"Schreiweis","year":"2019","journal-title":"J Med Internet Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3233\/SHTI190544","article-title":"Finding the needle in the hay stack: an open architecture to support diagnosis of undiagnosed patients","volume":"264","author":"Schaaf","year":"2019","journal-title":"Stud Health Technol Inform."},{"key":"B30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13023-019-1040-6","article-title":"Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study","volume":"14","author":"Ronicke","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0235574","DOI":"10.1371\/journal.pone.0235574","article-title":"Detecting rare diseases in electronic health records using machine learning and knowledge engineering: case study of acute hepatic porphyria","volume":"15","author":"Cohen","year":"2020","journal-title":"PLoS ONE."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e11301","DOI":"10.2196\/11301","article-title":"Utilization of electronic medical records and biomedical literature to support the diagnosis of rare diseases using data fusion and collaborative filtering approaches","volume":"6","author":"Shen","year":"2018","journal-title":"JMIR Med Inform."},{"key":"B33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3389\/fgene.2018.00587","article-title":"A machine learning system to support phenotype-based rare disease diagnosis","volume":"9","author":"Jia","year":"2018","journal-title":"Front Genet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/jamia\/ocab153","article-title":"The 2019 National Natural language processing (NLP) Clinical Challenges (n2c2)\/Open Health NLP (OHNLP) shared task on clinical concept normalization for clinical records","volume":"27","author":"Henry","year":"2020","journal-title":"J Am Med Inform Assoc."},{"key":"B35","doi-asserted-by":"publisher","first-page":"19012","DOI":"10.1038\/s41598-020-75912-x","article-title":"An artificial intelligence-based first-line defence against COVID-19: digitally screening citizens for risks via a chatbot","volume":"10","author":"Martin","year":"2020","journal-title":"Sci Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e21299","DOI":"10.2196\/21299","article-title":"Diagnostic accuracy of web-based COVID-19 symptom checkers: comparison study","volume":"22","author":"Munsch","year":"2020","journal-title":"J Med Internet Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00106-019-0666-y","volume":"67","author":"Nateqi","year":"2019","journal-title":"HNO."},{"key":"B38","doi-asserted-by":"publisher","first-page":"662254","DOI":"10.3389\/fgene.2021.662254","article-title":"Next-generation sequencing in newborn screening: a review of current state","volume":"12","author":"Remec","year":"2021","journal-title":"Front Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41431-020-00758-w","article-title":"Opportunistic genomic screening. Recommendations of the European Society of Human Genetics","volume":"29","author":"de Wert","year":"2021","journal-title":"Eur J Hum Genet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e20162252","DOI":"10.1542\/peds.2016-2252","article-title":"Newborn sequencing in genomic medicine and public health","volume":"139","author":"Berg","year":"2017","journal-title":"Pediatrics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1017\/S0016672315000178","article-title":"Challenges of using next generation sequencing in newborn screening","volume":"97","author":"Reinstein","year":"2015","journal-title":"Genet Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1038\/s41436-019-0527-9","article-title":"Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease","volume":"21","author":"Kishnani","year":"2019","journal-title":"Genet Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00415-009-5219-y","article-title":"Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations","volume":"256","author":"Oba-Shinjo","year":"2009","journal-title":"J Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.gene.2015.02.023","article-title":"Novel GAA mutations in patients with Pompe disease","volume":"561","author":"Tura\u00e7a","year":"2015","journal-title":"Gene."},{"key":"B45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/genes11020135","article-title":"Novel mutations found in individuals with adult-onset Pompe disease","volume":"11","author":"Aung-Htut","year":"2020","journal-title":"Genes"},{"key":"B46","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.nmd.2014.06.438","article-title":"Screening for late-onset Pompe disease in Finland","volume":"24","author":"Palmio","year":"2014","journal-title":"Neuromuscul Disord."},{"key":"B47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/ane.13133","article-title":"Screening for late-onset Pompe disease in Poland","volume":"140","author":"Jastrzebska","year":"2019","journal-title":"Acta Neurol Scand."},{"key":"B48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ane.12811","article-title":"Screening for late-onset Pompe disease in western Denmark","volume":"137","author":"Hansen","year":"2018","journal-title":"Acta Neurol Scand."},{"key":"B49","unstructured":""},{"key":"B50","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.nmd.2016.09.001","article-title":"The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: a multicenter study","volume":"26","author":"\u00dcnver","year":"2016","journal-title":"Neuromuscul Disord."},{"key":"B51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations","volume":"7","author":"Herzog","year":"2012","journal-title":"Orphanet J Rare Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/mus.21291","article-title":"novel mutation of the GAA gene in a Finnish late-onset Pompe disease patient: clinical phenotype and follow-up with enzyme replacement therapy","volume":"40","author":"Korpela","year":"2009","journal-title":"Muscle Nerve."},{"key":"B53","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10545-018-0243-7","article-title":"Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study","volume":"41","author":"Semplicini","year":"2018","journal-title":"J Inherit Metab Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nmd.2006.09.004","article-title":"Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations","volume":"17","author":"Palmer","year":"2007","journal-title":"Neuromuscul Disord."},{"key":"B55","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1212\/01.wnl.0000252798.25690.76","article-title":"Broad spectrum of Pompe disease in patients with the same c-32-13T->G haplotype","volume":"68","author":"Kroos","year":"2007","journal-title":"Neurology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1152\/jn.00190.2021","article-title":"Case studies in neuroscience: neuropathology and diaphragm dysfunction in ventilatory failure from late-onset Pompe disease","volume":"126","author":"Fuller","year":"2021","journal-title":"J Neurophysiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2017.09.008","article-title":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c-32-13T>G \u201clate-onset\u201d GAA variant","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol Genet Metab."},{"key":"B58","unstructured":"Werte Ziele und Vision - - Salzburger Landeskliniken (SALK)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"van der Beek","year":"2012","journal-title":"Orphanet J Rare Dis."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1108222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T01:00:04Z","timestamp":1682038804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1108222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":59,"alternative-id":["10.3389\/fneur.2023.1108222"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1108222","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1108222"}}